Medical devices, healthcare technology and the business of care
PMA approval · P250046

OncoMate MSI Dx Analysis System

Promega Corporation · Decision date Sep 15, 2026

MEDTECHLEDGER EXPLANATIONP250046

What did the FDA approve?

The FDA database entry records an approval decision dated September 15, 2026, for the OncoMate® MSI Dx Analysis System from Promega Corporation. The device is classified as a nucleic acid based assay for microsatellite instability under product code SFL and specialty Medical Genetics. The statement describes a qualitative multiplex PCR test that detects mononucleotide deletions in five microsatellite loci (BAT-25, BAT-26, NR-21, NR-24 and MONO-27) using DNA from FFPE solid tumor tissue, with a matched normal specimen from the same individual obtained from FFPE tissue or whole blood.

The system is specified for use with the Applied Biosystems® 3500 Dx Genetic Analyzer and OncoMate® MSI Dx Analysis Software. The statement reports the intended use as a companion diagnostic to identify MSI-H patients with advanced solid tumor cancers eligible for treatment with KEYTRUDA® in accordance with the approved therapeutic product labeling. The entry does not include supplement type or supplement reason fields, so no information about a changed item or relationship to a prior PMA is present in the record.

FDA approval order statement

Approval for the OncoMate MSI Dx Analysis System. The OncoMate MSI Dx Analysis System is a qualitative multiplex polymerase chain reaction (PCR) test intended to detect the deletion of mononucleotides in five microsatellite loci (BAT-25, BAT-26, NR-21, NR-24 and MONO-27) using DNA obtained from formalin-fixed, paraffin-embedded (FFPE) solid tumor tissue. The assay requires DNA from a matched normal specimen of the same individual, which may be obtained from FFPE tissue or whole blood. The OncoMate MSI Dx Analysis System is for use with the Applied Biosystems 3500 Dx Genetic Analyzer and OncoMate MSI Dx Analysis Software.The OncoMate MSI Dx Analysis System is intended for use as a companion diagnostic to identify MSI-H patients with advanced solid tumor cancers eligible for treatment with KEYTRUDA in accordance with the approved therapeutic product labeling.
Regulatory pathway
Original PMA
Clinical specialty
Medical Genetics
Decision date
Sep 15, 2026

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P250046
Regulatory pathway
Premarket approval application
Product code
SFL
Decision code
APPR
Decision date
Sep 15, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Nucleic Acid Based Assay, Microsatellite Instability.

Product code
SFL
FDA device class
3

The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.

FDA decision timeline

  1. P250046 received

    Application receipt date recorded by FDA.

  2. P250046 · FDA decision

    APPR

Timeline entries are records held by MedtechLedger for P250046. View FDA’s full supplement list.

Related devices and submissions

Explore the linked device profile

No additional submissions with a verified PMA or product-code relationship are linked here.

Regulatory context

An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Promega Corporation

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
2800 Woods Hollow Rd., Madison, WI, 53711

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records